1
|
Case Study: The Weighty Issue of Treatment Options for Obese Dialysis Patients. J Ren Nutr 2024:S1051-2276(24)00065-7. [PMID: 38685393 DOI: 10.1053/j.jrn.2024.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Revised: 04/13/2024] [Accepted: 04/15/2024] [Indexed: 05/02/2024] Open
Abstract
Obesity is a complex chronic disease and common comorbidity in kidney failure and is the leading causes of death and disability in this population. Guidelines do not specifically address the preferred weight management option(s) for obesity while on dialysis. Large body size is a limiting factor for consideration of a kidney transplantation. We report on a successful bariatric surgery with a young adult after 5.5 years on dialysis with hope for a future transplant. Success was demonstrated with progressive weight loss without adverse changes in renal clinical markers accompanied by improvements in exercise tolerance and health status thereby improving her suitability for a kidney transplant. Further studies and guidelines are needed to address weight loss options for those with obesity on dialysis and want to lose weight.
Collapse
|
2
|
Abstract
The burden of chronic kidney disease (CKD) has increased exponentially worldwide but more so in low- and middle-income countries. Specific risk factors in these regions expose their populations to an increased risk of CKD, such as genetic risk with APOL1 among populations of West African heritage or farmers with CKD of unknown etiology that spans various countries across several continents to immigrant/indigenous populations in both low- and high-income countries. Low- and middle-income economies also have the double burden of communicable and noncommunicable diseases, both contributing to the high prevalence of CKD. The economies are characterized by low health expenditure, sparse or nonexistent health insurance and welfare programs, and predominant out-of-pocket spending for medical care. This review highlights the challenges in populations with CKD from low-resource settings globally and explores how health systems can help ameliorate the CKD burden.
Collapse
|
3
|
POS-040 RENAL OUTCOMES FOLLOWING ELECTIVE WITHDRAWAL OF LONG-TERM STABLE RAAS-BLOCKADE IN CHRONIC KIDNEY DISEASE PATIENTS PRESENTING WITH PROGRESSIVE ACUTE KIDNEY INJURY. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.048] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
4
|
POS-647 COMBINED HOME-HEMODIALYSIS PLUS IN-CENTER HEMODIALYSIS HYBRID REGIMEN AS A FAMILY-FRIENDLY WORK-FRIENDLY OPTION - THE FIRST OF ITS KIND. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
5
|
POS-143 BENRAZILUMAB SUBSTITUTION MONOTHERAPY IS EFFECTIVE IN SYMPTOMATIC ASTHMA EXACERBATIONS OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
6
|
World Kidney Day 2021 with the theme of living well with kidney disease; a review of current concepts. JOURNAL OF PREVENTIVE EPIDEMIOLOGY 2021. [DOI: 10.34172/jpe.2021.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Since 2006, by considering one dimension of kidney disease, each year, the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF) have consistently and unanimously declared a World Kidney Day (WKD) around a specific kidney disease to increase the global awareness about kidney diseases. WKD, which is celebrated in more than 150 countries worldwide, is an international kidney health awareness campaign emphasizing the importance of the kidneys to reduce the global prevalence of kidney diseases and their related health problems by promoting patients and providing education. The present review aims to summarize the themes of previous WKD campaigns and the advocacy of the 2021 WKD campaign theme "Living well with kidney disease". The 2021 WKD Steering Committee advocates for the empowerment of CKD patients, their family members, and care partners, along with both drug and non-drug therapeutic programs to achieve better health outcomes.
Collapse
|
7
|
MO218ALTERNATING EPISODES OF TRUE HYPERKALEMIA AND PSEUDOHYPERKALEMIA IN ADULT SICKLE CELL DISEASE - A NEPHROLOGIST'S DILEMA. Nephrol Dial Transplant 2021. [DOI: 10.1093/ndt/gfab092.0096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background and Aims
To illustrate the phenomenon of alternating true hyperkalemia and pseudohyperkalemia in adult sickle cell disease.
Method
Case Report
Results
Sickle cell disease (SCD) predisposes the patient to recurrent episodes of acute painful hemolytic crisis. Sickle cell nephropathy (SCN) is not uncommon in adult patients. The presence of sickled erythrocytes in the renal medullary vessels is the hallmark of the disease and renal manifestations include renal ischemia, microinfarcts, renal papillary necrosis and renal tubular abnormalities with variable clinical presentations. Furthermore, acute hemolytic crisis can be complicated by sepsis. Hemolysis, specifically, intravascular hemolysis, can produce hyperkalemia. Additionally, reduced glomerular filtration rate from SCN predisposes to hyperkalemia. Pseudo-hyperkalemia was first reported by Hartmann and Mellinkoff in 1955 as a marked elevation of serum potassium levels in the absence of clinical evidence of electrolyte imbalance. In pseudohyperkalmia, simultaneously estimated serum potassium exceeds plasma potassium by >0.4 mmol/L. This is often associated with moderate to severe thrombocytosis or leukocytosis. Clearly, hyperkalemia is a potentially lethal condition. At the same time, the institution of inappropriate treatment of pseudo-hyperkalemia leading to hypokalemia is also equally potentially lethal. We describe a 40-yo African American male patient with sickle cell anemia who exhibited alternating episodes of hyperkalemia and pseudo-hyperkalemia, during consecutive hospital admissions. Pseudohyperkalemia was associated with severe thrombocytosis complicating sepsis. EKG was normal despite measured serum potassium of 6.7 mmol/L (Figure).
Conclusion
We believe that this is the first report of adult SCD demonstrating alternating cycles of true hyperkalemia and pseudo-hyperkalemia at different times. We must draw attention to the new availability of the new potassium binders, Patiromer and sodium zirconium cyclosilicate. We would advocate for caution in the use of these potent potassium binders and to always give consideration to the presence of pseudo-hyperkalemia under appropriate clinical scenarios. We posit that providers managing adult patients with sickle cell disease must be aware of such a phenomenon to avoid the dangers of overtreatment of episodes of pseudo-hyperkalemia in such patients.
Collapse
|
8
|
MO170“SWEET HYPOXIA” WITH ACUTE KIDNEY INJURY: THE UNPREDICTABILITY OF ACUTE HYPOXIC RESPIRATORY FAILURE IN COVID-19 INFECTION - A COMMUNITY HOSPITAL EXPERIENCE. Nephrol Dial Transplant 2021. [PMCID: PMC8195208 DOI: 10.1093/ndt/gfab092.0048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background and Aims Severe COVID-19 infection may result in hypoxemic respiratory failure necessitating invasive mechanical ventilation. We revisit the phenomenon of asymptomatic patients despite very low pulse oximetry readings, the so-called “sweet hypoxia” or “happy hypoxia” or “silent hypoxemia”. We describe for the first time, the sequential chest radiographic images of the progressive radiological trajectory of COVID-19 pneumonia. Method Case Report. Results A 62-year old hypertensive obese Caucasian male, an ex-smoker, was diagnosed with mild community-acquired pneumonia in mid-March 2020, following evaluation for low grade fever. He had traveled to Florida and Texas in the previous month. He tested positive for COVID-19 by RT-PCR. A week later, he was admitted to a Community Hospital with one day history of new shortness of breath and loose stools. Vital signs were stable. Pulse oximeter was 96% on room air. He was fatigued with few bibasilar lung crackles. CBC was normal. Creatinine was 1.0 mg/dL. Abnormal laboratory: sodium 131 mmol/L, AST 50 iu/L, ALT 96 iu/L. Chest radiograph revealed new patchy left lower lobe airspace infiltrate (Figure 1B). EKG showed regular sinus rhythm of 96/min, QT interval 445 msec and PVCs. Treatment included nasal cannula oxygen, IV fluids, IV Azithromycin and IV Ceftriaxone. He improved the next day, requested discharge home, vital signs were stable, pulse oximetry was 91% on room air, sodium had normalized at 137 mmol/L and he was discharged home on Azithromycin 500 mg daily x 3 days and Cefdinir 300 mg BID x 5 days. He cheerfully went home. Later that night he quickly developed worsening dyspnea. He was readmitted about 18 hours post-discharge. Temperature 99.40F, blood pressure 161/101, pulse 100/min. He was tachypneic and pulse oximetry was 82% on room air. This improved to 93% on 4.5 LPM nasal cannula oxygen. Initial EKG was normal. New pertinent laboratory data: Bicarbonate 17 mmol/L, phosphorus 5.5 mg/dL, calcium 7.2 mg/dL, creatinine 1.1 mg/dL, BNP 31 pg/mL and lactic acid 1.2 mmol/L. PTT was 28.3 sec. HIV-1 p24 AG, HIV-1 AB, HIV-2 AB, HbSAG and Hepatitis C AB were negative. Chest radiograph showed worsening bilateral infiltrates (Figure 1C). He very quickly desaturated in the ED down to 81% despite high flow oxygen therapy. He was promptly intubated (Figure 2A). Oxygenation immediately improved. He was transferred to the ICU on IV Vancomycin and IV Cefepime. He developed septic shock and required IV Norepinephrine. With worsening chest radiographs, (Figures 2B & 2C), he was transferred to a tertiary medical center. On transfer, pertinent new data: creatinine 1.38 mg/dL, albumin 2.8 g/dL, Ferritin 2,573 ng/mL, LDH 534 u/L, CRP 6.0 mg/L, INR 1.2, D-Dimer 1.04, procalcitonin 0.38 ng/mL, WBC 13.3 x 109/L. EKG showed sinus bradycardia. Urine Legionnaire AG and Strep. Pneumonia AG were negative. IV Azithromycin 500 mg daily and IV Ceftriaxone 2 gm daily were administered for 8 days. Chloroquine phosphate 500 mg 2x daily was added. IV Norepinephrine was continued. IV fluids were withheld. The head of the bed was elevated to >300. DVT prophylaxis with SQ Enoxaparin and Vitamin C were administered. New blood cultures remained negative. COVID-19 RT-PCR after 3 days remained positive. He was extubated after 4 days and discharged home after 9 days with normalized creatinine of 1.03 mg/dL. Conclusion We have for the first time demonstrated the sequential chest radiographic images of the progressive radiological trajectory of COVID-19 pneumonia. The place of non-invasive ventilation demands further study. The so-called “sweet hypoxia” or “happy hypoxia” or “silent hypoxemia” in COVID-19 is revisited – indeed, it is not exactly limited to COVID-19 patients. The need to mitigate lung barotrauma is mandatory. Finally, prognostication of pneumonia in COVID-19 is unpredictable. Too early premature discharge from the hospital is strongly discouraged.
Collapse
|
9
|
Abstract
Hyperkalemia is an electrolyte abnormality with potentially life-threatening consequences. Despite various guidelines, no universally accepted consensus exists on best practices for hyperkalemia monitoring, with variations in precise potassium (K+) concentration thresholds or for the management of acute or chronic hyperkalemia. Based on the available evidence, this review identifies several critical issues and unmet needs with regard to the management of hyperkalemia. Real-world studies are needed for a better understanding of the prevalence of hyperkalemia outside the clinical trial setting. There is a need to improve effective management of hyperkalemia, including classification and K+ monitoring, when to reinitiate previously discontinued renin-angiotensin-aldosterone system inhibitor (RAASi) therapy, and when to use oral K+-binding agents. Monitoring serum K+ should be individualized; however, increased frequency of monitoring should be considered for patients with chronic kidney disease, diabetes, heart failure, or a history of hyperkalemia and for those receiving RAASi therapy. Recent clinical studies suggest that the newer K+ binders (patiromer sorbitex calcium and sodium zirconium cyclosilicate) may facilitate optimization of RAASi therapy. Enhancing the knowledge of primary care physicians and internists with respect to the safety profiles of these newer K+ binders may increase confidence in managing patients with hyperkalemia. Lastly, the availability of newer K+-binding agents requires further study to establish whether stringent dietary K+ restrictions are needed in patients receiving K+-binder therapy. Individualized monitoring of serum K+ among patients with an increased risk of hyperkalemia and the use of newer K+-binding agents may allow for optimization of RAASi therapy and more effective management of hyperkalemia.
Collapse
|
10
|
SAT-055 PHARMACOLOGIC DECONGESTIVE DIURESIS WITH INTRAVENOUS LOOP AND THIAZIDE DIURETICS IN TYPE 1 ACUTE CARDIORENAL SYNDROME – AN UNDERUTILIZED PARADIGM OF CARE IN RESOURCE-POOR SETTINGS. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
11
|
SAT-054 POLYURIC ACUTE KIDNEY INJURY FROM NON-DILATED OBSTRUCTIVE UROPATHY COMPLICATING RECURRENT ABDOMINOPELVIC SARCOMA. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
12
|
SUN-112 THE CKD EXPRESS APP ©: AN INNOVATIVE STATE-OF-THE-ART REVOLUTIONARY CKD HEALTH MANAGEMENT SYSTEM. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
13
|
SUN-231 THE CKD EXPRESS ©: THE VALUE CONTRIBUTION TO CHRONIC KIDNEY DISEASE CARE USING AN INNOVATIVE REMOTE EMR-BASED MONITORING SYSTEM - A VERMONT POPULATION HEALTH INITIATIVE. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
14
|
Rituximab in ANCA-associated vasculitis presenting with severe acute kidney injury; a case report. J Nephropharmacol 2019. [DOI: 10.15171/npj.2019.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
15
|
End of Life, Withdrawal, and Palliative Care Utilization among Patients Receiving Maintenance Hemodialysis Therapy. Clin J Am Soc Nephrol 2018; 13:1172-1179. [PMID: 30026285 PMCID: PMC6086702 DOI: 10.2215/cjn.00590118] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Accepted: 05/15/2018] [Indexed: 11/23/2022]
Abstract
BACKGROUND AND OBJECTIVES Withdrawal from maintenance hemodialysis before death has become more common because of high disease and treatment burden. The study objective was to identify patient factors and examine the terminal course associated with hemodialysis withdrawal, and assess patterns of palliative care involvement before death among patients on maintenance hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We designed an observational cohort study of adult patients on incident hemodialysis in a midwestern United States tertiary center, from January 2001 to November 2013, with death events through to November 2015. Logistic regression models evaluated associations between patient characteristics and withdrawal status and palliative care service utilization. RESULTS Among 1226 patients, 536 died and 262 (49% of 536) withdrew. A random sample (10%; 52 out of 536) review of Death Notification Forms revealed 73% sensitivity for withdrawal. Risk factors for withdrawal before death included older age, white race, palliative care consultation within 6 months, hospitalization within 30 days, cerebrovascular disease, and no coronary artery disease. Most withdrawal decisions were made by patients (60%) or a family member (33%; surrogates). The majority withdrew either because of acute medical complications (51%) or failure to thrive/frailty (22%). After withdrawal, median time to death was 7 days (interquartile range, 4-11). In-hospital deaths were less common in the withdrawal group (34% versus 46% nonwithdrawal, P=0.003). A third (34%; 90 out of 262) of those that withdrew received palliative care services. Palliative care consultation in the withdrawal group was associated with longer hemodialysis duration (odds ratio, 1.19 per year; 95% confidence interval, 1.10 to 1.3; P<0.001), hospitalization within 30 days of death (odds ratio, 5.78; 95% confidence interval, 2.62 to 12.73; P<0.001), and death in hospital (odds ratio, 1.92; 95% confidence interval, 1.13 to 3.27; P=0.02). CONCLUSIONS In this single-center study, the rate of hemodialysis withdrawals were twice the frequency previously described. Acute medical complications and frailty appeared to be driving factors. However, palliative care services were used in only a minority of patients.
Collapse
|
16
|
All-cause costs increase exponentially with increased chronic kidney disease stage. THE AMERICAN JOURNAL OF MANAGED CARE 2017; 23:S163-S172. [PMID: 28978205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE To evaluate the economic impact of chronic kidney disease (CKD) on US health plans. STUDY DESIGN A retrospective analysis identified patients with a renin-angiotensin-aldosterone system inhibitor (RAASi) prescription from an electronic medical record (EMR) database (Humedica); those with =90 days in =1 CKD stage were selected based on estimated glomerular filtration rate or diagnosis code, and a cohort on RAASi medications without CKD was selected. Costs for specific services obtained from OptumInsight were applied to services in EMR data of patients aged <65 years (commercial) and =65 years (Medicare). Dialysis costs were excluded. RESULTS The study included 106,050 patients with CKD and 56,761 no-CKD controls (90,302 commercial and 72,509 Medicare overall). Mean annualized all-cause costs increased exponentially with advancing stage, from $7537 (no CKD) to $76,969 (CKD stages 4-5) in the commercial group, and $8091 (no CKD) to $46,178 (CKD stages 4-5) in the Medicare group (P <.001; all comparisons with preceding disease stage). Mean costs for end-stage renal disease (ESRD) patients were $121,948 and $87,339 in the commercial and Medicare groups, respectively. Inpatient costs were the largest contributor to total costs, and their relative contribution increased with advancing CKD. CONCLUSIONS Cost to US health plans increases exponentially with each CKD stage progression. ESRD costs are even higher. Because readmissions lead to higher costs, efforts to reduce readmissions would result in cost reductions. Furthermore, healthcare reengineering paradigms that manage increasing comorbidities with advancing CKD, including heart failure, diabetes, and hyperkalemia, should offer additional potential for cost reductions.
Collapse
|
17
|
Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure. J Manag Care Spec Pharm 2017; 23:S10-S19. [PMID: 28485203 PMCID: PMC10408402 DOI: 10.18553/jmcp.2017.23.4-a.s10] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
UNLABELLED Virtual panel meetings were conducted among 7 physicians, all of whom are independent experts, including 3 nephrologists, 2 cardiologists, and 2 emergency medicine physicians (the panel). The panel met with the purpose of discussing the current treatment landscape, treatment challenges, economic impact, and gaps in care for patients with hyperkalemia that is associated with heart failure and chronic kidney disease. The stated goal of the panel discussion was to develop practical solutions in the identification and management of hyperkalemia in this patient population. The panel noted that hyperkalemia is a serious condition that can lead to life-threatening complications, yet the treatment paradigm for hyperkalemia has remained without major advances for approximately 50 years, until the approval of patiromer. A number of issues still exist in the management of this patient population, including the lack of uniform treatment guidelines and consensus regarding the approach to treatment. As part of its effort, the panel developed an algorithm, the Proposed Diagnostic Algorithm for Hyperkalemia Treatment in the Acute Care Setting/Chronic Care. The panel agreed that patiromer appears to be a viable option for the management of hyperkalemia in patients with chronic kidney disease and/or heart failure and in patients who experience chronic hyperkalemia. DISCLOSURES This panel discussion was funded by Relypsa and facilitated by Magellan Rx Management. Rafique is a principal investigator for Relypsa and serves as a consultant for Instrumentation Laboratory, Magellan Health, Relypsa, and ZS-Pharma. Butler serves as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CardioCell, Janssen, Merck, Novartis, Relypsa, and ZS-Pharma. Lopes and Farnum are employed by Magellan Rx Management. Rafique designed the management protocol for this panel discussion and contributed to the writing and editing of this report document. The other authors report no conflicting interests. Relypsa is the manufacturer of Veltassa (patiromer).
Collapse
|
18
|
Echocardiography Criteria for Structural Heart Disease in Patients With End-Stage Renal Disease Initiating Hemodialysis. J Am Coll Cardiol 2016; 67:1173-1182. [PMID: 26965538 DOI: 10.1016/j.jacc.2015.12.052] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Revised: 12/07/2015] [Accepted: 12/14/2015] [Indexed: 12/12/2022]
Abstract
BACKGROUND Cardiovascular disease among hemodialysis (HD) patients is linked to poor outcomes. The Acute Dialysis Quality Initiative Workgroup proposed echocardiographic (ECHO) criteria for structural heart disease (SHD) in dialysis patients. The association of SHD with important patient outcomes is not well defined. OBJECTIVES This study sought to determine prevalence of ECHO-determined SHD and its association with survival among incident HD patients. METHODS We analyzed patients who began chronic HD from 2001 to 2013 who underwent ECHO ≤1 month prior to or ≤3 months following initiation of HD (n = 654). RESULTS Mean patient age was 66 ± 16 years, and 60% of patients were male. ECHO findings that met 1 or more and ≥3 of the new criteria were discovered in 87% and 54% of patients, respectively. Over a median of 2.4 years, 415 patients died: 108 (26%) died within 6 months. Five-year mortality was 62%. Age- and sex-adjusted structural heart disease variables associated with death were left ventricular ejection fraction (LVEF) ≤45% (hazard ratio [HR]: 1.48; confidence interval [CI]: 1.20 to 1.83) and right ventricular (RV) systolic dysfunction (HR: 1.68; CI: 1.35 to 2.07). An additive of higher death risk included LVEF ≤45% and RV systolic dysfunction rather than neither (HR: 2.04; CI: 1.57 to 2.67; p = 0.53 for test for interaction). Following adjustment for age, sex, race, diabetic kidney disease, and dialysis access, RV dysfunction was independently associated with death (HR: 1.66; CI 1.34 to 2.06; p < 0.001). CONCLUSIONS SHD was common in our HD study population, and RV systolic dysfunction independently predicted mortality.
Collapse
|
19
|
Tolerability and Healthcare Utilization in Maintenance Hemodialysis Patients Undergoing Treatment for Tuberculosis-Related Conditions. Nephron Clin Pract 2016; 132:198-206. [PMID: 26859893 DOI: 10.1159/000444148] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Accepted: 01/19/2016] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND The incidence of tuberculosis (TB) in end-stage renal disease is significantly higher than that in the general population. Among those with kidney dysfunction, anti-TB treatment is associated with increased side effects, but the effect on healthcare utilization is unknown. Methods/Aim: To assess patient-reported symptoms, adverse effects and describe changes in healthcare utilization patterns during treatment for TB, we conducted a case series (n = 12) of patients receiving maintenance hemodialysis (HD) from Mayo Clinic Dialysis Services and concurrent drug therapy for TB from January 2002 through May 2014. Healthcare utilization (hospitalizations and emergency department (ED) visits independent of hospital admission) was compared before and during treatment. RESULTS Patients were treated for latent (n = 7) or active (n = 5) TB. The majority of patients with latent disease were treated with isoniazid (n = 5, 71%), while active-disease patients received a 4-drug regimen. Adverse effects were reported in 83% of patients. Compared to measurements prior to drug initiation, serum albumin and dialysis weights were similar at 3 months. Commonly reported anti-TB drug toxicities were described. More than half (58%) of the patients were hospitalized at least once. No ED or hospital admissions occurred in the period prior to drug therapy, but healthcare utilization increased during treatment in the latent disease group (hospitalization rate per person-month: pre 0 vs. post 1). CONCLUSIONS Among HD patients, anti-TB therapy is associated with frequently reported symptoms and increased healthcare utilization. Among this subset, patients receiving treatment for latent disease may be those with greatest increase in healthcare use. Careful monitoring and early complication detection may help optimize medication adherence and minimize hospitalizations.
Collapse
|
20
|
Syndrome of rapid onset ESRD accounted for high hemodialysis catheter use--results of a 13-year Mayo Clinic incident hemodialysis study. Ren Fail 2015; 37:1486-91. [PMID: 26375630 DOI: 10.3109/0886022x.2015.1088336] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND The syndrome of rapid onset end-stage renal disease (SORO-ESRD) was first described in the journal Renal Failure in 2010. This is an acute precipitate unpredictable yet irreversible ESRD following acute kidney injury (AKI), as distinct from "classic" ESRD where chronic kidney disease (CKD)-ESRD progression was linear, time-dependent, and predictable. The overall impact of SORO-ESRD on ESRD outcomes in the adult US ESRD population remains speculative and called for larger studies. METHODS A retrospective investigation of an incident adult ESRD population, Mayo Clinic, Rochester, 2001-2013. RESULTS One hundred and forty-nine of 1461 (10%) incident patients with ESRD had SORO-ESRD - M:F = 76:73, age 62 (19-95) years, 139 (93%) native kidneys, and 10 (7%) renal transplant recipients (RTRs). The modal age group was 71-80 years. A total of 147 (99%) SORO-ESRD patients started first hemodialysis treatment via a dialysis catheter. Kidney biopsy in 10 RTRs and 34 native kidneys revealed acute tubular necrosis (ATN) as the commonest pathology. Cardiac arrest remained the leading cause of death among SORO-ESRD patients. CONCLUSIONS SORO-ESRD accounted for 149 (10%) of 1461 incident ESRD patients. There was no gender disparity. The older population was more susceptible. Ninety-nine percent (99%) of SORO-ESRD patients started their first hemodialysis treatment via a dialysis catheter, a major negative impact on AV fistula first programs. ATN was the leading pathologic diagnosis. We conclude that SORO-ESRD contributes significantly to incident ESRD here in the USA including renal allograft loss. Efforts to reduce AKI incidence or renoprevention demand more attention and priority.
Collapse
|
21
|
SP353A MAYO CLINIC ROCHESTER THIRTEEN-YEAR RETROSPECTIVE INVESTIGATION OF THE SYNDROME OF RAPID ONSET END STAGE RENAL DISEASE (SORO-ESRD) IN AN INCIDENT ADULT HEMODIALYSIS COHORT, 2001–2013. Nephrol Dial Transplant 2015. [DOI: 10.1093/ndt/gfv192.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Nephroprevention in the oldest old with chronic kidney disease: Special considerations. World J Nephrol 2015; 4:1-5. [PMID: 25664242 PMCID: PMC4317619 DOI: 10.5527/wjn.v4.i1.1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2014] [Revised: 11/07/2014] [Accepted: 11/19/2014] [Indexed: 02/06/2023] Open
Abstract
Nephroprevention strategies are crucial for handling chronic kidney disease (CKD) complications, and slowing its progression. However, these preventative measures should be guided by major geriatrics principles in order to help nephrologists to adequately handle the oldest old with CKD. These geriatric concepts consist of taking into account the relevance of choosing an individualized therapy, handling clinical frailty, and keeping a geriatric perspective which means that a good quality of life is sometimes a more important therapeutic objective in octogenarians than merely prolonging life. Even though nephroprevention strategies for treating the oldest old with CKD are basically similar to those applied to younger patients such as low sodium and protein diet, optimized hemoglobin levels, blood pressure and metabolic control, the treating physician or care provider must at all times be ready to make fundamental adjustments and tweak patient care paradigms and objectives if and when the initial therapeutic options applied have caused unintended clinical consequences and complications. Additionally, the sarcopenia status should also be evaluated and treated in very old CKD patients.
Collapse
|
23
|
|
24
|
|
25
|
|
26
|
CELL PHYSIOLOGY AND ELECTROLYTES. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria. Nephron Clin Pract 2013; 123:123-8. [PMID: 23860441 DOI: 10.1159/000353223] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Continental Africa is facing an epidemic of chronic kidney disease (CKD). APOL1 risk variants have been shown to be strongly associated with an increased risk for non-diabetic kidney disease including HIV nephropathy, primary non-monogenic focal and segmental glomerulosclerosis, and hypertension-attributed nephropathy among African ancestry populations in the USA. The world's highest frequencies of APOL1 risk alleles have been reported in West African nations, overlapping regions with a high incidence of CKD and hypertension. One such region is south-eastern Nigeria, and therefore we sought to quantify the association of APOL1 risk alleles with CKD in this region. METHODS APOL1 risk variants were genotyped in a case-control sample set consisting of non-diabetic, CKD patients (n = 44) and control individuals (n = 43) from Enugu and Abakaliki, Nigeria. RESULTS We found a high frequency of two APOL1 risk alleles in the general population of Igbo people of south-eastern Nigeria (23.3%). The two APOL1 risk allele frequency in the CKD patient group was 66%. Logistic regression analysis under a recessive inheritance model showed a strong and significant association of APOL1 two-risk alleles with CKD, yielding an odds ratio of 6.4 (unadjusted p = 1.2E-4); following correction for age, gender, HIV and BMI, the odds ratio was 4.8 (adjusted p = 5.1E-03). CONCLUSION APOL1 risk variants are common in the Igbo population of south-eastern Nigeria, and are also highly associated with non-diabetic CKD in this area. APOL1 may explain the increased prevalence of CKD in this region.
Collapse
|
28
|
Penultimate pulse wave velocity, better than baseline pulse wave velocity, predicted mortality in Italian ESRD cohort study - a case for daily hemodialysis for ESRD patients with accelerated pulse wave velocity changes. GIORNALE ITALIANO DI NEFROLOGIA : ORGANO UFFICIALE DELLA SOCIETA ITALIANA DI NEFROLOGIA 2013; 30:gin/00072.22. [PMID: 23832464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
BACKGROUND Cardiac disease remains the major cause of death among ESRD patients. Indeed, the risk of cardiovascular events in ESRD is reported to be at least 3.4 fold higher than that of the general population. Moreover, annual mortality rates among ESRD patients on hemodialysis approximate 20%, with cardiovascular disease accounting for almost half of this mortality profile. Despite this knowledge, so far we have been unable to identify treatable pathogenetic factors among ESRD patients to help reverse these poor cardiovascular outcomes. The difficulty to prognosticate cardiovascular mortality in ESRD remains elusive. However, in 2011, our group, for the first time, had demonstrated that cyclic variations of arterial stiffness as measured by pulse wave velocity (PWV) before and after hemodialysis determined mortality differences within an ESRD cohort. We have therefore examined the impact of individual patient-level translational PWV changes over time on mortality outcomes in an Italian ESRD cohort. STUDY DESIGN AND SETTING Prospective observational study, 2007-2010, in an Italian ESRD cohort who underwent in-center outpatient conventional thrice weekly hemodialysis. METHODS PWV was measured by the foot-to-foot method and repeated after six months. Coronary artery calcification (CAC) was measured at 0, 12 and 24 months. Routine clinical data and patient demographics were recorded and mortality outcomes were analyzed. RESULTS Between 2007 and 2010, 466 Italian ESRD patients, 229 males and 237 females, age 19-97 (65.6) years, were followed up for 28.9 months. 128 patients (74M:54F) died. The major causes of death were acute myocardial infarction (AMI) in 47 (37%) patients (age 70, 26M:21F) and sudden death (SD) in 29 (23%) patients (age 72, 19M:10F). Paired PWV data was available in 308 surviving patients and in 106 patients who died. Baseline PWV was lower in surviving vs dead patients 8.46 +/- 1.8 vs 9.43 +/- 3.75 (p=0.0005). Repeat PWV values were unchanged in the 308 survivors (8.46 +/- 1.8 vs 8.53 +/- 1.85, p=0.5, NS). Repeat PWV values increased in the 106 patients who died from 9.43 +/- 3.75 to 12.11 +/- 4.18 (p<0.0001). Of the 29 patients who died from SD, death occurred <12 hours after the last dialysis (ATLD) in 7, >24 hours ATLD in 20 and >48 hours ATLD in 17. Of the 47 patients who died from AMI, 6 died <12 hours ATLD, 35 died >24 hours ATLD and 23 died >48 hours ATLD. Of the 14 ESRD patients in the cohort that died from hyperkalemia, 3 died <12 hours ATLD, 11 died >24 hours ATLD, and 7 died >48 hours ATLD. CAC data scatter did not allow for adequate statistical subgroup analysis but overall, baseline CAC values were higher in the AMI/SD dead patients vs surviving patients. CONCLUSIONS This is the first report to show a scalable and direct relationship between translational follow up PWV changes after six months versus observed cardiovascular mortality in an ESRD cohort. We have shown, for the first time, that penultimate PWV, better than baseline PWV, predicted cardiovascular mortality in this ESRD cohort. Moreover, higher proportions of the ESRD deaths from AMI, SD and hyperkalemia occurred during the long inter-dialytic (weekend) period when ESRD patients went for 3 days without hemodialysis. We propose that PWV be monitored among all new ESRD patients, and be repeated after six months of initiation of chronic hemodialysis. Our group had earlier demonstrated in 2012 that daily dialysis reduced PWV in chronic hemodialysis patients. From these study findings, we have proposed that ESRD patients who exhibit elevated initial PWV values, or more so, ESRD patients who demonstrate accelerated PWV values after six months on maintenance chronic hemodialysis should be converted to daily hemodialysis protocol. Furthermore, such patients may require more intense cardiovascular analysis by cardiologists. Further research into new preventative or therapeutic options in this area of ESRD care is warranted.
Collapse
|
29
|
Renoprotection and the Bardoxolone Methyl Story - Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents. NEPHRON EXTRA 2013; 3:36-49. [PMID: 23687511 PMCID: PMC3656681 DOI: 10.1159/000351044] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
In the June 2011 issue of the New England Journal of Medicine, the BEAM (Bardoxolone Methyl Treatment: Renal Function in CKD/Type 2 Diabetes) trial investigators rekindled new interest and also some controversy regarding the concept of renoprotection and the role of renoprotective agents, when they reported significant increases in the mean estimated glomerular filtration rate (eGFR) in diabetic chronic kidney disease (CKD) patients with an eGFR of 20-45 ml/min/1.73 m(2) of body surface area at enrollment who received the trial drug bardoxolone methyl versus placebo. Unfortunately, subsequent phase IIIb trials failed to show that the drug is a safe alternative renoprotective agent. Current renoprotection paradigms depend wholly and entirely on angiotensin blockade; however, these agents [angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)] have proved to be imperfect renoprotective agents. In this review, we examine the mechanistic limitations of the various previous randomized controlled trials on CKD renoprotection, including the paucity of veritable, elaborate and systematic assessment methods for the documentation and reporting of individual patient-level, drug-related adverse events. We review the evidence base for the presence of putative, multiple independent and unrelated pathogenetic mechanisms that drive (diabetic and non-diabetic) CKD progression. Furthermore, we examine the validity, or lack thereof, of the hyped notion that the blockade of a single molecule (angiotensin II), which can only antagonize the angiotensin cascade, would veritably successfully, consistently and unfailingly deliver adequate and qualitative renoprotection results in (diabetic and non-diabetic) CKD patients. We clearly posit that there is this overarching impetus to arrive at the inference that multiple, disparately diverse and independent pathways, including any veritable combination of the mechanisms that we examine in this review, and many more others yet to be identified, do concurrently and asymmetrically contribute to CKD initiation and propagation to end-stage renal disease (ESRD) in our CKD patients. We conclude that current knowledge of CKD initiation and progression to ESRD, the natural history of CKD and the impacts of acute kidney injury on this continuum remain in their infancy and call for more research. Finally, we suggest a new classification scheme for renoprotective agents: (1) the single-pathway blockers that block a single putative pathogenetic pathway involved in CKD progression, as typified by ACE inhibitors and/or ARBs, and (2) the multiple-pathway blockers that are able to block or antagonize the effects of multiple pathogenetic pathways through their ability to simultaneously block, downstream, the effects of several pathways or mechanisms of CKD to ESRD progression and could therefore concurrently interfere with several unrelated upstream pathways or mechanisms. We surmise that maybe the ideal and truly renoprotective agent, clearly a multiple-pathway blocker, is on the horizon. This calls for more research efforts from all.
Collapse
|
30
|
Predialysis nephrology care of older patients approaching end-stage renal disease. ACTA ACUST UNITED AC 2012; 171:2066; author reply 2067. [PMID: 22158585 DOI: 10.1001/archinternmed.2011.586] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
31
|
Acute kidney injury - Human studies. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Pathophysiology and clinical studies in CKD 1-5. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
|
34
|
222: Chronic Kidney Disease Progression to ESRD: Smooth and Progressive vs Uneven and Staccato Patterns? – A Mayo Clinic PBRN-Based 82-Month Analysis of 100 High-Risk CKD Patients – Implications for a Paradigm Change in Reno-Protection. Am J Kidney Dis 2010. [DOI: 10.1053/j.ajkd.2010.02.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
35
|
221: Bilateral Lower Extremity Sequential Compression Devices (SCDS) for the Management of Intra-Dialytic Hypotension – A New Approach to an Old Problem. Am J Kidney Dis 2010. [DOI: 10.1053/j.ajkd.2010.02.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
36
|
224: To Stent or Not to Stent: Renal Artery Stenosis–A Mayo Health System Hypertension Clinic 82-Month PBRN-Based Patient-Level Prospective Data Analysis of 26 High-Risk CKD Patients With Renal Artery Stenosis Presenting With Acute Kidney Injury. Am J Kidney Dis 2010. [DOI: 10.1053/j.ajkd.2010.02.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
37
|
223: Nondilated Obstructive Uropathy – An Unrecognized Cause of Acute Renal Failure in Hospitalized US Patients: Three Case Reports Seen Over Six Months in a North-Western Wisconsin Nephrology Practice. Am J Kidney Dis 2010. [DOI: 10.1053/j.ajkd.2010.02.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
38
|
158. Am J Kidney Dis 2007. [DOI: 10.1053/j.ajkd.2007.02.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
39
|
159. Am J Kidney Dis 2007. [DOI: 10.1053/j.ajkd.2007.02.166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
40
|
|
41
|
Unilateral hyperlucency and lung abscess in a 20-year-old woman. South Med J 2002; 95:1109-10. [PMID: 12356128 DOI: 10.1097/00007611-200209000-00047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Right atrial mobile thrombus and pulmonary thromboembolism complicating hemorrhagic Campylobacter jejuni colitis. South Med J 2002; 95:1107-9. [PMID: 12356127 DOI: 10.1097/00007611-200209000-00046] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
43
|
|
44
|
Abstract
Cytomegalovirus (CMV) remains a major viral pathogen complicating renal transplantation. Tubulointerstitial nephritis is the commonly acknowledged and well-characterized pathologic feature of renal allograft CMV disease. There is controversy about whether there is a distinct entity as a CMV glomerulopathy in the absence of tubulointerstitial disease. We describe two patients with renal allograft dysfunction who displayed distinct features of CMV glomerular vasculopathy, in the absence of overt viral cytopathic changes involving the tubules.
Collapse
|
45
|
Gender differences in responsiveness to erythropoietin. Am J Kidney Dis 2002; 39:442-3. [PMID: 11840394 DOI: 10.1053/ajkd.2002.31195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
46
|
Retroperitoneal fibrosis: unusual cause of low back pain. South Med J 2001; 94:735-7. [PMID: 11531184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Retroperitoneal fibrosis (RPF) is an uncommon collagen vascular disease with a male predominance. Back pain with no specific radiation pattern is common, and bilateral obstructive uropathy, potentially reversible, is frequently associated with RPF. We report a case of RPF and review its diagnosis and management.
Collapse
|
47
|
Glycosuria in alcoholics. Alcohol diabetes, transient hyperglycemia, renal tubular syndrome or factitious dipstick test result? Nephron Clin Pract 2001; 87:287-8. [PMID: 11287768 DOI: 10.1159/000045930] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
48
|
|
49
|
Inherited thrombophilia, hypercoagulability, and risk factors for atherosclerosis. Mayo Clin Proc 2000; 75:870-1. [PMID: 10943248 DOI: 10.4065/75.8.870-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
50
|
Successful thrombolytic therapy for massive pulmonary embolism. South Med J 2000; 93:327-9. [PMID: 10728526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
The use and scope of thrombolytic therapy in the management of pulmonary embolism (PE) continues to evolve. The results of small studies suggest that thrombolytic therapy might have an impact on survival in massive PE with cardiogenic shock; however, no large studies to further this notion exist. Furthermore, the expanded application of thrombolytic therapy to patients with PE and right ventricular dysfunction (RVD) but without overt hemodynamic collapse remains controversial. We report successful use of the thrombolytic agent tissue plasminogen activator (tPA) in the management of life-threatening PE with RVD without overt cardiovascular collapse. We present evidence for the meritorious use of thrombolytic therapy in this category of PE patients. We believe that a broadened application of thrombolytic therapy to patients with PE and RVD but without cardiogenic shock, especially in younger patients, is beneficial and worth the risk.
Collapse
|